INDIANAPOLIS, June 13, 2020 /PRNewswire/ -- New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide ...
Once-weekly treatment for adults with type 2 diabetes comes in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 10, 2014 /PRNewswire/ -- The newest GLP-1 receptor agonist treatment option to ...
AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...
The new indication reflects the differentiated patient population of REWIND, the Trulicity cardiovascular outcomes trial. While all participants had CV risk factors, the study consisted primarily of ...
Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise The single-dose pen does not require mixing nor ...
INDIANAPOLIS, June 9, 2019 /PRNewswire/ -- Detailed results from REWIND, the Trulicity ® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major cardiovascular ...
"The incidence of type 2 diabetes among youth and adolescents is on the rise, particularly among minority populations, and the disease can be even more progressive and difficult to treat than in ...
Older female adult smiling while purchasing some medication after asking does Medicare cover Trulicity Doctors may prescribe drugs like Trulicity to help manage a person’s diabetes, but only certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results